Immuneering
IMRX
38 hedge funds and large institutions have $10.9M invested in Immuneering in 2024 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 8 increasing their positions, 18 reducing their positions, and 27 closing their positions.
11% less capital invested
Capital invested by funds: $12.3M → $10.9M (-$1.41M)
17.67% less ownership
Funds ownership: 32.36% → 14.69% (-18%)
36% less funds holding
Funds holding: 59 → 38 (-21)
56% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 18
78% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 27
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$586K |
| 2 |
T
Tidemark
San Diego,
California
|
+$75.4K |
| 3 |
SM
Southport Management
Wilson,
Wyoming
|
+$65.3K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$35.6K |
| 5 |
Corient Private Wealth
Miami,
Florida
|
+$29.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$2.41M |
| 2 |
Millennium Management
New York
|
-$1.03M |
| 3 |
Goldman Sachs
New York
|
-$949K |
| 4 |
PM
Prosight Management
Dallas,
Texas
|
-$524K |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$492K |
IMRX Hedge Fund Activity: Q3 2024 in Review
38 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Immuneering (IMRX) for Q3 2024, worth a combined $10.9M — down 11% from $12.3M a quarter earlier.
Sellers outnumbered buyers: 27 funds closed out of IMRX and 6 opened new positions — a net loss of 21 holders — while 18 trimmed existing stakes and 8 added.
The largest buyer was Morgan Stanley, adding an estimated $586K. The largest seller was Citadel Advisors, exiting entirely with an estimated $2.41M sold.
- 38 institutional investors held Immuneering (IMRX) as of Q3 2024, down from 59 in Q2 2024.
- Funds reported $10.9M of Immuneering stock for Q3 2024, down 11% quarter-over-quarter.
- 6 funds opened new Immuneering positions in Q3 2024 and 27 closed out, a net change of -21 holders.
- The largest Immuneering buyer in Q3 2024 was Morgan Stanley, an estimated $586K added.
- The largest Immuneering seller in Q3 2024 was Citadel Advisors, an estimated $2.41M sold.
Based on aggregated 13F filings for Q3 2024.